MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin

ConclusionsOur data indicate that MDMX expression may serve as an independent unfavorable prognostic factor for NSCLC patient outcome, which in turn may at least partly be due to the ability of the MDMX protein to regulate the proliferative capacity and chemosensitivity of NSCLC cells.

http://link.springer.com/10.1007/s13402-017-0325-9

Source: Cellular Oncology - May 31, 2017 Category: Cancer & Oncology Source Type: research

More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Study